autoRIC® for Hematopoietic stem cells

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Hematopoietic stem cells
autoRIC® - Device
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new way to reduce heart damage in children undergoing cancer treatment. If successful, it could lead to fewer heart problems for these kids down the road.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Hematopoietic stem cells

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 18-24 months from start of enrollment

Month 24
Adverse events

Trial Safety

Safety Progress

1 of 3

Other trials for Hematopoietic stem cells

Trial Design

2 Treatment Groups

Control Group
1 of 2
Therapeutic Group
1 of 2
Active Control
Experimental Treatment

40 Total Participants · 2 Treatment Groups

Primary Treatment: autoRIC® · No Placebo Group · N/A

Therapeutic Group
Device
Experimental Group · 1 Intervention: autoRIC® · Intervention Types: Device
Control GroupNoIntervention Group · 1 Intervention: Control Group · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 18-24 months from start of enrollment

Who is running the clinical trial?

Children's Hospital Medical Center, CincinnatiLead Sponsor
747 Previous Clinical Trials
5,417,478 Total Patients Enrolled
Thomas RyanPrincipal InvestigatorChildren's Hospital Medical Center, Cincinnati
1 Previous Clinical Trials

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
This product can handle blood pressure being pumped up to the user's upper arm.
Patients aged 10 years or older are considered pediatric, adolescent, or young adult patients.
This announcement is to inform potential participants that the BMT Biorepository (2012-1156) is open for enrollment

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.